Whatsapp Share

It�s speaking English that kills you.

I was advised by a fellow speaker, many years my senior, to practice my Spanish. And here�s why: We all know that Heart Disease is the #1 cause of death in the U.S. But think hard about this:

In Japan, they’ve got a diet that is low in fat and they have less heart disease than the US. While in France, the diet is very high in fat, and they also have less heart disease than in the US.

In China, almost nobody drinks red wine and the heart disease rate is lower than in the US. But in Spain, everybody drinks too much red wine and sure enough they have less heart disease than the US.

Algeria has the lowest sexual activity rate, and they’ve got less heart disease than in the US. But Brazil has the highest sexual activity rate and sure enough…the heart disease ratio is lower than in the US.

His sage wisdom to me? Drink, eat and make merry all you want. It’s speaking English that kills you.

Alex

Recent Posts

Oasis Calls for CEO Dismissal, Submits Shareholder Proposals for New Directors at Hokuetsu AGM (Securities Code: 3865 JT)

*Oasis proposes dismissal of Hokuetsu CEO Sekio Kishimoto at upcoming AGM * Oasis nominates five…

27 mins ago

Seadrill Announces Two New Drillship Commitments

HAMILTON, Bermuda--(BUSINESS WIRE)--Seadrill Limited (“Seadrill” or the “Company”) (NYSE & OSE: SDRL) today announced contract…

2 hours ago

Kasada Secures #4 Spot on Australia’s Best Workplaces™ in Technology List for 2024

Dedication to Fostering a Culture of Care, Innovation, and Impact Drives Global Growth and Recognition…

2 hours ago

GAMCO Board Declares Special Dividend of $0.20 per share and Regular Quarterly Dividend of $0.04 per share

GREENWICH, Conn., May 07, 2024 (GLOBE NEWSWIRE) -- GAMCO Investors, Inc. (“GAMI”) (OTCQX: GAMI) announced…

3 hours ago

Coeur to Participate in Upcoming Canaccord Global Metals & Mining Conference

CHICAGO--(BUSINESS WIRE)--Coeur Mining, Inc.’s (“Coeur” or the “Company”) (NYSE: CDE) Senior Vice President and Chief…

3 hours ago

LEO Pharma Announces Topline Results of Phase 3 Trial in China for Enstilar® (LEO 90100) Demonstrating Superiority in Adult Chinese Subjects With Stable Plaque Psoriasis

Enstilar® (LEO 90100) showed superiority over Daivobet® ointment in primary and both secondary endpoints in…

5 hours ago